Global Hunter Syndrome Treatment
Global Hunter Syndrome Treatment

Hunter Syndrome Treatment Comprehensive Study by Type (Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT), Others), End-user (Life Science Companies, Research Institutes, Hospital) Players and Region - Global Market Outlook to 2026

Hunter Syndrome Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 248 Pages 212 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Hunter Syndrome Treatment Market?

Hunter syndrome, also called mucopolysaccharidosis II or MPS II, is a very rare, inherited genetic disorder caused by a missing or malfunctioning enzyme. This syndrome is more common in boys and their body doesn't have enough of the enzyme iduronate 2-sulfatase. There is no cure for Hunter Syndrome and treatment involves managing symptoms and complications. The factors such as Increased Prevalence of Hunter Syndrome among Boys and Increasing Awareness about the Availability of Treatment Options for Hunter Syndrome are the key drivers for the global Hunter Syndrome Treatment market. In addition, the Introduction of the Novel Treatment Option for Hunter Syndrome also fueling the market growth. However, the High Cost of Treatment and Non-Availability of a Complete Cure for Hunter Syndrome may hinder the market growth.

The market study is being classified by Type (Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT) and Others) and major geographies with country level break-up.

Takeda Pharmaceutical Company (Japan), GC Pharma (South Korea), JCR Pharmaceuticals Co Ltd. (Japan), RegenxBio Inc. (United States), Sangamo Therapeutics, Inc. (United States), ArmaGen Inc. (United States), Inventiva S.A. (France), Denali Therapeutics Inc. (United States), Bioasis Technologies Inc. (Canada) and Esteve (Spain) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Hunter Syndrome Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Hunter Syndrome Treatment market by Type, Application and Region.

On the basis of geography, the market of Hunter Syndrome Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Hunter Syndrome among Boys
  • Increasing Awareness about Availability of Treatment Options for Hunter Syndrome

Market Trend
  • Introduction of Novel Treatment Option for Hunter Syndrome

Restraints
  • High Cost of the Treatment

Opportunities
  • Growth in the Healthcare Industry in Developing Regions
  • Increasing Research and Development Funding

Challenges
  • Non-Availability of Complete Cure for Hunter Syndrome





Key Target Audience
Hunter Syndrome Treatment Providers, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Enzyme Replacement Therapy (ERT)
  • Hematopoietic Stem Cell Transplant (HSCT)
  • Others
By End-user
  • Life Science Companies
  • Research Institutes
  • Hospital

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Hunter Syndrome among Boys
      • 3.2.2. Increasing Awareness about Availability of Treatment Options for Hunter Syndrome
    • 3.3. Market Challenges
      • 3.3.1. Non-Availability of Complete Cure for Hunter Syndrome
    • 3.4. Market Trends
      • 3.4.1. Introduction of Novel Treatment Option for Hunter Syndrome
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hunter Syndrome Treatment, by Type, End-user and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Hunter Syndrome Treatment (Value)
      • 5.2.1. Global Hunter Syndrome Treatment by: Type (Value)
        • 5.2.1.1. Enzyme Replacement Therapy (ERT)
        • 5.2.1.2. Hematopoietic Stem Cell Transplant (HSCT)
        • 5.2.1.3. Others
      • 5.2.2. Global Hunter Syndrome Treatment by: End-user (Value)
        • 5.2.2.1. Life Science Companies
        • 5.2.2.2. Research Institutes
        • 5.2.2.3. Hospital
      • 5.2.3. Global Hunter Syndrome Treatment Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Hunter Syndrome Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Takeda Pharmaceutical Company (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GC Pharma (South Korea)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. JCR Pharmaceuticals Co Ltd. (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. RegenxBio Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sangamo Therapeutics, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. ArmaGen Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Inventiva S.A. (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Denali Therapeutics Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bioasis Technologies Inc. (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Esteve (Spain)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hunter Syndrome Treatment Sale, by Type, End-user and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Hunter Syndrome Treatment (Value)
      • 7.2.1. Global Hunter Syndrome Treatment by: Type (Value)
        • 7.2.1.1. Enzyme Replacement Therapy (ERT)
        • 7.2.1.2. Hematopoietic Stem Cell Transplant (HSCT)
        • 7.2.1.3. Others
      • 7.2.2. Global Hunter Syndrome Treatment by: End-user (Value)
        • 7.2.2.1. Life Science Companies
        • 7.2.2.2. Research Institutes
        • 7.2.2.3. Hospital
      • 7.2.3. Global Hunter Syndrome Treatment Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hunter Syndrome Treatment: by Type(USD Million)
  • Table 2. Hunter Syndrome Treatment Enzyme Replacement Therapy (ERT) , by Region USD Million (2015-2020)
  • Table 3. Hunter Syndrome Treatment Hematopoietic Stem Cell Transplant (HSCT) , by Region USD Million (2015-2020)
  • Table 4. Hunter Syndrome Treatment Others , by Region USD Million (2015-2020)
  • Table 5. Hunter Syndrome Treatment: by End-user(USD Million)
  • Table 6. Hunter Syndrome Treatment Life Science Companies , by Region USD Million (2015-2020)
  • Table 7. Hunter Syndrome Treatment Research Institutes , by Region USD Million (2015-2020)
  • Table 8. Hunter Syndrome Treatment Hospital , by Region USD Million (2015-2020)
  • Table 9. South America Hunter Syndrome Treatment, by Country USD Million (2015-2020)
  • Table 10. South America Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 11. South America Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 12. Brazil Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 13. Brazil Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 14. Argentina Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 15. Argentina Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 16. Rest of South America Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 17. Rest of South America Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 18. Asia Pacific Hunter Syndrome Treatment, by Country USD Million (2015-2020)
  • Table 19. Asia Pacific Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 20. Asia Pacific Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 21. China Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 22. China Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 23. Japan Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 24. Japan Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 25. India Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 26. India Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 27. South Korea Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 28. South Korea Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 29. Taiwan Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 30. Taiwan Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 31. Australia Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 32. Australia Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 33. Rest of Asia-Pacific Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 34. Rest of Asia-Pacific Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 35. Europe Hunter Syndrome Treatment, by Country USD Million (2015-2020)
  • Table 36. Europe Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 37. Europe Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 38. Germany Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 39. Germany Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 40. France Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 41. France Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 42. Italy Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 43. Italy Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 44. United Kingdom Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 45. United Kingdom Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 46. Netherlands Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 47. Netherlands Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 48. Rest of Europe Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 49. Rest of Europe Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 50. MEA Hunter Syndrome Treatment, by Country USD Million (2015-2020)
  • Table 51. MEA Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 52. MEA Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 53. Middle East Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 54. Middle East Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 55. Africa Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 56. Africa Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 57. North America Hunter Syndrome Treatment, by Country USD Million (2015-2020)
  • Table 58. North America Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 59. North America Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 60. United States Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 61. United States Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 62. Canada Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 63. Canada Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 64. Mexico Hunter Syndrome Treatment, by Type USD Million (2015-2020)
  • Table 65. Mexico Hunter Syndrome Treatment, by End-user USD Million (2015-2020)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Hunter Syndrome Treatment: by Type(USD Million)
  • Table 77. Hunter Syndrome Treatment Enzyme Replacement Therapy (ERT) , by Region USD Million (2021-2026)
  • Table 78. Hunter Syndrome Treatment Hematopoietic Stem Cell Transplant (HSCT) , by Region USD Million (2021-2026)
  • Table 79. Hunter Syndrome Treatment Others , by Region USD Million (2021-2026)
  • Table 80. Hunter Syndrome Treatment: by End-user(USD Million)
  • Table 81. Hunter Syndrome Treatment Life Science Companies , by Region USD Million (2021-2026)
  • Table 82. Hunter Syndrome Treatment Research Institutes , by Region USD Million (2021-2026)
  • Table 83. Hunter Syndrome Treatment Hospital , by Region USD Million (2021-2026)
  • Table 84. South America Hunter Syndrome Treatment, by Country USD Million (2021-2026)
  • Table 85. South America Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 86. South America Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 87. Brazil Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 88. Brazil Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 89. Argentina Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 90. Argentina Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 91. Rest of South America Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 92. Rest of South America Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 93. Asia Pacific Hunter Syndrome Treatment, by Country USD Million (2021-2026)
  • Table 94. Asia Pacific Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 95. Asia Pacific Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 96. China Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 97. China Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 98. Japan Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 99. Japan Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 100. India Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 101. India Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 102. South Korea Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 103. South Korea Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 104. Taiwan Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 105. Taiwan Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 106. Australia Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 107. Australia Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 108. Rest of Asia-Pacific Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 109. Rest of Asia-Pacific Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 110. Europe Hunter Syndrome Treatment, by Country USD Million (2021-2026)
  • Table 111. Europe Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 112. Europe Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 113. Germany Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 114. Germany Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 115. France Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 116. France Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 117. Italy Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 118. Italy Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 119. United Kingdom Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 120. United Kingdom Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 121. Netherlands Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 122. Netherlands Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 123. Rest of Europe Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 124. Rest of Europe Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 125. MEA Hunter Syndrome Treatment, by Country USD Million (2021-2026)
  • Table 126. MEA Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 127. MEA Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 128. Middle East Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 129. Middle East Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 130. Africa Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 131. Africa Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 132. North America Hunter Syndrome Treatment, by Country USD Million (2021-2026)
  • Table 133. North America Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 134. North America Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 135. United States Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 136. United States Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 137. Canada Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 138. Canada Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 139. Mexico Hunter Syndrome Treatment, by Type USD Million (2021-2026)
  • Table 140. Mexico Hunter Syndrome Treatment, by End-user USD Million (2021-2026)
  • Table 141. Research Programs/Design for This Report
  • Table 142. Key Data Information from Secondary Sources
  • Table 143. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hunter Syndrome Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Hunter Syndrome Treatment: by End-user USD Million (2015-2020)
  • Figure 6. South America Hunter Syndrome Treatment Share (%), by Country
  • Figure 7. Asia Pacific Hunter Syndrome Treatment Share (%), by Country
  • Figure 8. Europe Hunter Syndrome Treatment Share (%), by Country
  • Figure 9. MEA Hunter Syndrome Treatment Share (%), by Country
  • Figure 10. North America Hunter Syndrome Treatment Share (%), by Country
  • Figure 11. Global Hunter Syndrome Treatment share by Players 2020 (%)
  • Figure 12. Global Hunter Syndrome Treatment share by Players (Top 3) 2020(%)
  • Figure 13. Global Hunter Syndrome Treatment share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Takeda Pharmaceutical Company (Japan) Revenue, Net Income and Gross profit
  • Figure 16. Takeda Pharmaceutical Company (Japan) Revenue: by Geography 2020
  • Figure 17. GC Pharma (South Korea) Revenue, Net Income and Gross profit
  • Figure 18. GC Pharma (South Korea) Revenue: by Geography 2020
  • Figure 19. JCR Pharmaceuticals Co Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 20. JCR Pharmaceuticals Co Ltd. (Japan) Revenue: by Geography 2020
  • Figure 21. RegenxBio Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. RegenxBio Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Sangamo Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Sangamo Therapeutics, Inc. (United States) Revenue: by Geography 2020
  • Figure 25. ArmaGen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. ArmaGen Inc. (United States) Revenue: by Geography 2020
  • Figure 27. Inventiva S.A. (France) Revenue, Net Income and Gross profit
  • Figure 28. Inventiva S.A. (France) Revenue: by Geography 2020
  • Figure 29. Denali Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Denali Therapeutics Inc. (United States) Revenue: by Geography 2020
  • Figure 31. Bioasis Technologies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 32. Bioasis Technologies Inc. (Canada) Revenue: by Geography 2020
  • Figure 33. Esteve (Spain) Revenue, Net Income and Gross profit
  • Figure 34. Esteve (Spain) Revenue: by Geography 2020
  • Figure 35. Global Hunter Syndrome Treatment: by Type USD Million (2021-2026)
  • Figure 36. Global Hunter Syndrome Treatment: by End-user USD Million (2021-2026)
  • Figure 37. South America Hunter Syndrome Treatment Share (%), by Country
  • Figure 38. Asia Pacific Hunter Syndrome Treatment Share (%), by Country
  • Figure 39. Europe Hunter Syndrome Treatment Share (%), by Country
  • Figure 40. MEA Hunter Syndrome Treatment Share (%), by Country
  • Figure 41. North America Hunter Syndrome Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Takeda Pharmaceutical Company (Japan)
  • GC Pharma (South Korea)
  • JCR Pharmaceuticals Co Ltd. (Japan)
  • RegenxBio Inc. (United States)
  • Sangamo Therapeutics, Inc. (United States)
  • ArmaGen Inc. (United States)
  • Inventiva S.A. (France)
  • Denali Therapeutics Inc. (United States)
  • Bioasis Technologies Inc. (Canada)
  • Esteve (Spain)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation